GWM
LGND icon

Geneos Wealth Management’s Ligand Pharmaceuticals LGND Stock Holding History

Geneos Wealth Management’s Portfolio LGND Stock Details LGND Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-119
Closed -$13.5K – 2876
2025
Q2 		$13.5K Hold
119
– – ﹤0.01% 2201
2025
Q1 		$12.5K Buy
119
+58
+95% +$6.56K ﹤0.01% 2164
2024
Q4 		$6.54K Hold
61
– – ﹤0.01% 2222
2024
Q3 		$6.11K Buy
+61
New +$6.14K ﹤0.01% 2008
2019
Q4 		– Sell
-22
Closed -$1K – 2563
2019
Q3 		$1K Hold
22
– – ﹤0.01% 2415
2019
Q2 		$1K Buy
+22
New +$1.62K ﹤0.01% 2415
2018
Q4 		– Sell
-152
Closed -$26K – 2441
2018
Q3 		$26K Hold
152
– – ﹤0.01% 1460
2018
Q2 		$19K Buy
+152
New +$17K ﹤0.01% 1471

Other funds holding LGND

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $23.2B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $15.4B AUM 30.35% 1-Year Est. Return
CC
Chicago Capital Chicago, Illinois $4.15B AUM 31.09% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Geneos Wealth Management's LGND Position: Q3 2025 in Review

Geneos Wealth Management sold out of Ligand Pharmaceuticals (LGND) in Q3 2025, closing a stake of 119 shares — an estimated $13.5K sold.

Geneos Wealth Management first reported a position in LGND in Q2 2018 and held it in 8 quarters. The position peaked at $26K in Q3 2018. 314 funds tracked by Wall St. Rank hold LGND as of Q3 2025.

  • Geneos Wealth Management reported no remaining Ligand Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Geneos Wealth Management sold 119 Ligand Pharmaceuticals shares in Q3 2025, an estimated $13.5K.
  • Geneos Wealth Management first reported a position in Ligand Pharmaceuticals in Q2 2018 and held it in 8 quarters.
  • Geneos Wealth Management's Ligand Pharmaceuticals position peaked at $26K in Q3 2018.
  • 314 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q3 2025.

Based on Geneos Wealth Management's 13F filing for Q3 2025, filed 22 Oct 2025.